Granite Investment Partners LLC Trims Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Granite Investment Partners LLC lowered its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,087 shares of the medical instruments supplier’s stock after selling 2,215 shares during the quarter. Granite Investment Partners LLC owned about 0.42% of ICU Medical worth $15,841,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Sterling Capital Management LLC lifted its holdings in shares of ICU Medical by 813.5% in the 4th quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier’s stock worth $105,000 after acquiring an additional 602 shares during the last quarter. CenterBook Partners LP purchased a new stake in ICU Medical in the fourth quarter valued at approximately $1,467,000. Martingale Asset Management L P lifted its stake in ICU Medical by 1,100.0% during the fourth quarter. Martingale Asset Management L P now owns 16,800 shares of the medical instruments supplier’s stock worth $2,607,000 after purchasing an additional 15,400 shares in the last quarter. Invesco Ltd. boosted its position in shares of ICU Medical by 12.4% during the fourth quarter. Invesco Ltd. now owns 113,153 shares of the medical instruments supplier’s stock worth $17,558,000 after buying an additional 12,489 shares during the period. Finally, Bank of Montreal Can grew its stake in shares of ICU Medical by 5.4% in the fourth quarter. Bank of Montreal Can now owns 4,051 shares of the medical instruments supplier’s stock valued at $629,000 after buying an additional 208 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

ICUI stock opened at $142.65 on Friday. ICU Medical, Inc. has a 1 year low of $93.36 and a 1 year high of $196.26. The firm has a market capitalization of $3.50 billion, a P/E ratio of -31.21 and a beta of 0.86. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business’s 50-day moving average is $148.29 and its two-hundred day moving average is $160.95.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research reports. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, April 4th. Raymond James set a $97.00 price objective on shares of ICU Medical in a research note on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, ICU Medical has an average rating of “Buy” and an average price target of $168.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.